Attached files
| file | filename |
|---|---|
| EX-10.34 - SHORT TERM NOTE AGREEMENT BETWEEN CHRISTOPHER CHIPMAN AND VIRPAX PHARMACEUTICALS - Virpax Pharmaceuticals, Inc. | fs12021a3ex10-34_virpaxphar.htm |
| EX-10.33 - SHORT TERM NOTE AGREEMENT BETWEEN ANTHONY P. MACK AND VIRPAX PHARMACEUTICALS, IN - Virpax Pharmaceuticals, Inc. | fs12021a3ex10-33_virpaxphar.htm |
| EX-10.32 - FOURTH AMENDMENT TO THE SERVICES CONVERTIBLE PROMISSORY NOTE, DATED AS OF DECEMB - Virpax Pharmaceuticals, Inc. | fs12021a3ex10-32_virpaxphar.htm |
| EX-10.31 - AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT BETWEEN NANOMERICS LT - Virpax Pharmaceuticals, Inc. | fs12021a3ex10-31_virpaxphar.htm |
| S-1/A - REGISTRATION STATEMENT - Virpax Pharmaceuticals, Inc. | fs12021a3_virpaxpharma.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement of Virpax Pharmaceuticals, Inc. on Form S-1/A to be filed on or about January 8, 2021 of our report dated August 10, 2020, except with respect to Note 13, as to which the date is November 19, 2020, on our audits of the financial statements as of December 31, 2019 and 2018 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Philadelphia, Pennsylvania
January 8, 2021